#56P An Institutional study evaluating the benefit of blood NGS over conventional hotspot molecular genetic testing in **TAT 2022** metastatic adenocarcinoma lung

Rajashree Ashwath¹ Amit Rauthan² Poonam Patil³ Prathyush Vundemodalu⁴ Chinnu Jomi⁵ Department of Medical Oncology Manipal hospitals Bengaluru India

Introduction

 Management of metastatic adenocarcinoma lung is based on detection of molecular alterations. Common methods of testing are single gene testing on tissue for EGFR by PCR, ALK by IHC and ROS1by FISH based methods. At the present time, tissue based NGS(next generation sequencing) has been widely use 	v • M A hi
for the detection of aberrations in genes such as EGFR,ALK,ROS1,BRAF, NTRK and ERBB2, RET and MET.	
• Though tissue based NGS testing is considered standard, blood/liquid based biopsy NGS testing is becoming valuable especially when there is lack of tissue for testing.	Fig 1.
Objective	■ Adeno
 To evaluate the added benefit by doing blood based NGS testing 	SquamousOthers

REFERENCES


1.David M. DiBardino, MD, David W Rawson, MD1, Anjali Saqi, MD2, Jonas J. Heymann, MD2, Carlos A Pagan, MD2, and William A. Bulman, MD3

Methods

Retrospective study of 182 patients of metastatic ing cancer.

Diagnosed between Jan 2019-Nov 2021, at Manipal ospitals Bangalore aged 35-75yrs.

Aen were 134 (73.6%) and 48 (26.3%) were women. denocarcinoma 147 (80.7%) was the most common istology followed by 29 (15.9%) squamous cell arcinoma and others were 6(3.2%) (Fig 1.)



esults	Table 1
All 147 (80.7%) adenocarcinoma patients	A
underwent tumor tissue testing for EGFR	EGFI
mutation by PCR, ALK by IHC and ROS1 fusions	
by FISH methods.	ALK
	ROS1
Tissue based molecular alterations (Fig 2.) were	MET
detected in 50 (34%) patients and 97(65.9%)	MET
patients were tested negative.	HER
In this study we further evaluated, 97 (65.9%)	HER RAS
patients who had wild type alterations by	KAS TP53
conventional hotspot method to liquid/blood	RET
based NGS testing.(Fig 3.)	HER
\mathbf{e} \mathbf{e} \mathbf{e} \mathbf{e}	
Due to logistic issues only 67 (69 %) patients out of 97 underwent liquid/blood based NGS testing.	
	Patient
ľ	oanel v
t	esting
Fig 3. MOLECULAR ANALYSIS BY BLOOD NGS • V	Ne det
ON PATIENTS WITH WILD TYPE ON TISSUE	
DASED CONVENTIONAL LESITING	lterati
41(42%) 30 (30.9%) a	ind out
	6) pati
40 - V	which
ین ₁₀ 30 - 26(26.8%)	esting
	U
	More v
10 - 10 - 1	egular
	~

Not detected

Detected

Not tested

(logistic issues)



ManipalHospitals LIFE'S ON 🔡

. Molecular alterations detected on NGS BLOOD

ALTERATIONS DETECTED	PATIENTS = 41 $(42%)$
R [14 common , 5 uncommon , 2 EGFR exon 20 insertion]	21 (21.6)
	3 (3.09)
1	1 (1.03)
Fexon 14 skipping	1 (1.03)
Camplification	1 (1.03)
2 neu mutation	2 (2.06)
2 neu amplification	1 (1.03)
mutation	5 (5.15)
3	3 (3.09)
	1 (1.03)
R2 exon 20 insertion	2 (2.06)

nclusion

ts should be evaluated with extensive NGS with liquid /tissue biopsy if conventional is wild type for molecular alterations.

tected additional 41 (61 %) molecular tions in patients by doing liquid NGS testing it of these, the added benefit was seen in 27 (40 tients where targetable drugs were utilized would have missed if only conventional based was done.

validated platforms are required for doing r liquid biopsy NGS testing in India.

rajshri87@gmail.com